Showing results (61-70 of 82) with videos related to
Sort By:
Pageof 9
British Journal of Haematology|November 25, 2003
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's diseaseFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.Blood|May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndromeHesham M Amin, Iman Jilani, Elihu H Estey, et al.Oncotarget|March 22, 2021
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.Blood|June 21, 2008
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasmsConstantine S Tam, Roberto M Nussenzveig, Uday Popat, et al.Leukemia|September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cellsDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2022
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia CellsUri Rozovski, Ivo Veletic, David M Harris, et al.Cancer Cell|September 29, 2015
hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic MalignanciesMiguel Gallardo, Hun Ju Lee, Xiaorui Zhang, et al.Leukemia|April 4, 2025
CLL cell-derived exosomes alter the immune and hematopoietic systemsIvo Veletic, David M Harris, Uri Rozovski, et al.Haematologica|May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trialSrdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.Blood|February 5, 2010
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsAlfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, et al.Pageof 9